comparemela.com

Latest Breaking News On - Cantargia - Page 2 : comparemela.com

Cantargia AB: Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

LUND, Sweden, Feb. 23, 2023 /PRNewswire/ Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis

Dennis riedlDurani reynalsAgostina stradellaPrnewswire cantargiaCatalan institute of oncologySpanish breast cancer groupPrincipal investigatorCatalan instituteNasdaq stockholm

Cantargia AB: Cantargia publishes full year report for 2022

LUND, Sweden, Feb. 23, 2023 /PRNewswire/ Cantargia AB's ("Cantargia") full year report for 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Dennis riedlPatrik renbladChief financial officerNasdaq stockholmYear report

Cantargia AB: Invitation to presentation of Cantargia s Year-end report of 2022 on February 23 at 3 00 p m CET

Cantargia AB will publish the company's Year-end report for January-December 2022 on Thursday, February 23, 2023, at 08:30 a.m. CET. LUND, Sweden, Feb. 14, 2023 /PRNewswire/ In conjunction

Cantargia inbjudanNasdaq stockholmMarcel torney

Cantargia AB: Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

LUND, Sweden, Feb. 1, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer

Patrik renbladPrnewswire cantargiaSchwierige zeitenSynact pharmaLund universityBusiness administrationNasdaq stockholmChief financial officerFinance directorPatient access

Cantargia AB: Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application

LUND, Sweden, Jan. 13, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today announced that the Good Laboratory Practice (GLP) toxicity study for its anti-inflammatory

Prnewswire cantargiaGood laboratory practiceNasdaq stockholm

vimarsana © 2020. All Rights Reserved.